Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit “Regina Elena” National Cancer Institute
Background The majority of patients with glioblastoma (GBM) experience disease progression. At recurrence, treatment options have limited efficacy. Many studies report a limited and short duration response rate. Although clinical trials represent the “gold standard” for providing evidence on efficac...
Gespeichert in:
| Veröffentlicht in: | Neurological sciences 2022-09, Vol.43 (9), p.5533-5541 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5541 |
|---|---|
| container_issue | 9 |
| container_start_page | 5533 |
| container_title | Neurological sciences |
| container_volume | 43 |
| creator | Villani, Veronica Prosperini, Luca Lecce, Mario Tanzilli, Antonio Farneti, Alessia Benincasa, Dario Telera, Stefano Marucci, Laura Piludu, Francesca Pace, Andrea |
| description | Background
The majority of patients with glioblastoma (GBM) experience disease progression. At recurrence, treatment options have limited efficacy. Many studies report a limited and short duration response rate. Although clinical trials represent the “gold standard” for providing evidence on efficacy of specific treatment strategies, real-world data can be considered more representative of the “real” GBM population.
Objective
To describe the management of GBM recurrence in a large real-world sample.
Methods
We analysed retrospectively the data stored in the database of the Neuro-oncology Unit, IRCCS “Regina Elena” National Cancer Institute, Rome, Italy. We considered only data of patients with histological diagnosis of GBM and disease recurrence during their follow-up. We excluded patients who did not receive treatment after the diagnosis.
Results
We analysed 422 patients (64% males, 36% females) with a mean age of 59.6 (range 16–87) years. At GBM recurrence, 135 (32.0%) patients underwent palliative care, and 287 (68.0%) underwent other treatments. Patients on palliative care were older, had a worse performance status, and a shorter time between GBM diagnosis and its recurrence. Patients who received chemotherapy in combination with other treatments (surgery and/or radiation therapy) at GBM recurrence had a longer survival than those in palliative care (
p
|
| doi_str_mv | 10.1007/s10072-022-06172-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2672319911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2703182176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-78e3e8dc04bb1e6b1228a74d3185a4afd6c1ac7697a84795af8ee24dbd3bdd703</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EoqXwAhyQJS69pHjsJE64oGpVoFLVShU9R4492U3l2MV2VOXWC28BL9cnwe0uIHHoYTy_NN_8Y-kn5C2wI2BMfogPLy8Yz1VDVsszsg9VywpRyub5TkMjyz3yKsZrxhiUIF6SPVHVJUgB--THJeo5BHSJru3oe6ti8pP6SG83o97QFFClKU8_0WOatS1ufbCGxjSbhQ7BTzRtkJ7jHHzhnfbWrxd65cZE7-9-XuJ6dIqeWHTq_u4XPVdp9E5ZulJOY6CnLqYxzQlfkxeDshHf7PoBufp88m31tTi7-HK6Oj4rNK_qVMgGBTZGs7LvAeseOG-ULI2AplKlGkytQWlZt1I1pWwrNTSIvDS9Eb0xkokDcrj1vQn--4wxddMYNVqrHPo5dryWXEDbAmT0_X_otZ9D_nymshM0HGSdKb6ldPAxBhy6mzBOKiwdsO4hnm4bUpdD6h5D6pa89G5nPfcTmr8rf1LJgNgCMY_cGsO_20_Y_gbUL6Dr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2703182176</pqid></control><display><type>article</type><title>Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit “Regina Elena” National Cancer Institute</title><source>SpringerLink Journals - AutoHoldings</source><creator>Villani, Veronica ; Prosperini, Luca ; Lecce, Mario ; Tanzilli, Antonio ; Farneti, Alessia ; Benincasa, Dario ; Telera, Stefano ; Marucci, Laura ; Piludu, Francesca ; Pace, Andrea</creator><creatorcontrib>Villani, Veronica ; Prosperini, Luca ; Lecce, Mario ; Tanzilli, Antonio ; Farneti, Alessia ; Benincasa, Dario ; Telera, Stefano ; Marucci, Laura ; Piludu, Francesca ; Pace, Andrea</creatorcontrib><description>Background
The majority of patients with glioblastoma (GBM) experience disease progression. At recurrence, treatment options have limited efficacy. Many studies report a limited and short duration response rate. Although clinical trials represent the “gold standard” for providing evidence on efficacy of specific treatment strategies, real-world data can be considered more representative of the “real” GBM population.
Objective
To describe the management of GBM recurrence in a large real-world sample.
Methods
We analysed retrospectively the data stored in the database of the Neuro-oncology Unit, IRCCS “Regina Elena” National Cancer Institute, Rome, Italy. We considered only data of patients with histological diagnosis of GBM and disease recurrence during their follow-up. We excluded patients who did not receive treatment after the diagnosis.
Results
We analysed 422 patients (64% males, 36% females) with a mean age of 59.6 (range 16–87) years. At GBM recurrence, 135 (32.0%) patients underwent palliative care, and 287 (68.0%) underwent other treatments. Patients on palliative care were older, had a worse performance status, and a shorter time between GBM diagnosis and its recurrence. Patients who received chemotherapy in combination with other treatments (surgery and/or radiation therapy) at GBM recurrence had a longer survival than those in palliative care (
p
< 0.001). Surgery or radiation therapy alone did not have any effect on survival as compared with palliative care (
p
< 0.001).
Conclusion
This study confirms the importance of a multidisciplinary approach even at GBM recurrence, suggesting that combination treatments play a key role in management of disease.</description><identifier>ISSN: 1590-1874</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-022-06172-y</identifier><identifier>PMID: 35641731</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Brain cancer ; Chemotherapy ; Clinical trials ; Diagnosis ; Glioblastoma ; Medicine ; Medicine & Public Health ; Neurology ; Neuroradiology ; Neurosciences ; Neurosurgery ; Oncology ; Original Article ; Palliative care ; Patients ; Psychiatry ; Radiation therapy ; Surgery ; Survival</subject><ispartof>Neurological sciences, 2022-09, Vol.43 (9), p.5533-5541</ispartof><rights>Fondazione Società Italiana di Neurologia 2022</rights><rights>2022. Fondazione Società Italiana di Neurologia.</rights><rights>Fondazione Società Italiana di Neurologia 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-78e3e8dc04bb1e6b1228a74d3185a4afd6c1ac7697a84795af8ee24dbd3bdd703</cites><orcidid>0000-0001-5747-2808</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10072-022-06172-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10072-022-06172-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35641731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Villani, Veronica</creatorcontrib><creatorcontrib>Prosperini, Luca</creatorcontrib><creatorcontrib>Lecce, Mario</creatorcontrib><creatorcontrib>Tanzilli, Antonio</creatorcontrib><creatorcontrib>Farneti, Alessia</creatorcontrib><creatorcontrib>Benincasa, Dario</creatorcontrib><creatorcontrib>Telera, Stefano</creatorcontrib><creatorcontrib>Marucci, Laura</creatorcontrib><creatorcontrib>Piludu, Francesca</creatorcontrib><creatorcontrib>Pace, Andrea</creatorcontrib><title>Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit “Regina Elena” National Cancer Institute</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><addtitle>Neurol Sci</addtitle><description>Background
The majority of patients with glioblastoma (GBM) experience disease progression. At recurrence, treatment options have limited efficacy. Many studies report a limited and short duration response rate. Although clinical trials represent the “gold standard” for providing evidence on efficacy of specific treatment strategies, real-world data can be considered more representative of the “real” GBM population.
Objective
To describe the management of GBM recurrence in a large real-world sample.
Methods
We analysed retrospectively the data stored in the database of the Neuro-oncology Unit, IRCCS “Regina Elena” National Cancer Institute, Rome, Italy. We considered only data of patients with histological diagnosis of GBM and disease recurrence during their follow-up. We excluded patients who did not receive treatment after the diagnosis.
Results
We analysed 422 patients (64% males, 36% females) with a mean age of 59.6 (range 16–87) years. At GBM recurrence, 135 (32.0%) patients underwent palliative care, and 287 (68.0%) underwent other treatments. Patients on palliative care were older, had a worse performance status, and a shorter time between GBM diagnosis and its recurrence. Patients who received chemotherapy in combination with other treatments (surgery and/or radiation therapy) at GBM recurrence had a longer survival than those in palliative care (
p
< 0.001). Surgery or radiation therapy alone did not have any effect on survival as compared with palliative care (
p
< 0.001).
Conclusion
This study confirms the importance of a multidisciplinary approach even at GBM recurrence, suggesting that combination treatments play a key role in management of disease.</description><subject>Brain cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Diagnosis</subject><subject>Glioblastoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Neurosurgery</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Palliative care</subject><subject>Patients</subject><subject>Psychiatry</subject><subject>Radiation therapy</subject><subject>Surgery</subject><subject>Survival</subject><issn>1590-1874</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcFu1DAQhi0EoqXwAhyQJS69pHjsJE64oGpVoFLVShU9R4492U3l2MV2VOXWC28BL9cnwe0uIHHoYTy_NN_8Y-kn5C2wI2BMfogPLy8Yz1VDVsszsg9VywpRyub5TkMjyz3yKsZrxhiUIF6SPVHVJUgB--THJeo5BHSJru3oe6ti8pP6SG83o97QFFClKU8_0WOatS1ufbCGxjSbhQ7BTzRtkJ7jHHzhnfbWrxd65cZE7-9-XuJ6dIqeWHTq_u4XPVdp9E5ZulJOY6CnLqYxzQlfkxeDshHf7PoBufp88m31tTi7-HK6Oj4rNK_qVMgGBTZGs7LvAeseOG-ULI2AplKlGkytQWlZt1I1pWwrNTSIvDS9Eb0xkokDcrj1vQn--4wxddMYNVqrHPo5dryWXEDbAmT0_X_otZ9D_nymshM0HGSdKb6ldPAxBhy6mzBOKiwdsO4hnm4bUpdD6h5D6pa89G5nPfcTmr8rf1LJgNgCMY_cGsO_20_Y_gbUL6Dr</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Villani, Veronica</creator><creator>Prosperini, Luca</creator><creator>Lecce, Mario</creator><creator>Tanzilli, Antonio</creator><creator>Farneti, Alessia</creator><creator>Benincasa, Dario</creator><creator>Telera, Stefano</creator><creator>Marucci, Laura</creator><creator>Piludu, Francesca</creator><creator>Pace, Andrea</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5747-2808</orcidid></search><sort><creationdate>20220901</creationdate><title>Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit “Regina Elena” National Cancer Institute</title><author>Villani, Veronica ; Prosperini, Luca ; Lecce, Mario ; Tanzilli, Antonio ; Farneti, Alessia ; Benincasa, Dario ; Telera, Stefano ; Marucci, Laura ; Piludu, Francesca ; Pace, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-78e3e8dc04bb1e6b1228a74d3185a4afd6c1ac7697a84795af8ee24dbd3bdd703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brain cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Diagnosis</topic><topic>Glioblastoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Neurosurgery</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Palliative care</topic><topic>Patients</topic><topic>Psychiatry</topic><topic>Radiation therapy</topic><topic>Surgery</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Villani, Veronica</creatorcontrib><creatorcontrib>Prosperini, Luca</creatorcontrib><creatorcontrib>Lecce, Mario</creatorcontrib><creatorcontrib>Tanzilli, Antonio</creatorcontrib><creatorcontrib>Farneti, Alessia</creatorcontrib><creatorcontrib>Benincasa, Dario</creatorcontrib><creatorcontrib>Telera, Stefano</creatorcontrib><creatorcontrib>Marucci, Laura</creatorcontrib><creatorcontrib>Piludu, Francesca</creatorcontrib><creatorcontrib>Pace, Andrea</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Villani, Veronica</au><au>Prosperini, Luca</au><au>Lecce, Mario</au><au>Tanzilli, Antonio</au><au>Farneti, Alessia</au><au>Benincasa, Dario</au><au>Telera, Stefano</au><au>Marucci, Laura</au><au>Piludu, Francesca</au><au>Pace, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit “Regina Elena” National Cancer Institute</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><addtitle>Neurol Sci</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>43</volume><issue>9</issue><spage>5533</spage><epage>5541</epage><pages>5533-5541</pages><issn>1590-1874</issn><eissn>1590-3478</eissn><abstract>Background
The majority of patients with glioblastoma (GBM) experience disease progression. At recurrence, treatment options have limited efficacy. Many studies report a limited and short duration response rate. Although clinical trials represent the “gold standard” for providing evidence on efficacy of specific treatment strategies, real-world data can be considered more representative of the “real” GBM population.
Objective
To describe the management of GBM recurrence in a large real-world sample.
Methods
We analysed retrospectively the data stored in the database of the Neuro-oncology Unit, IRCCS “Regina Elena” National Cancer Institute, Rome, Italy. We considered only data of patients with histological diagnosis of GBM and disease recurrence during their follow-up. We excluded patients who did not receive treatment after the diagnosis.
Results
We analysed 422 patients (64% males, 36% females) with a mean age of 59.6 (range 16–87) years. At GBM recurrence, 135 (32.0%) patients underwent palliative care, and 287 (68.0%) underwent other treatments. Patients on palliative care were older, had a worse performance status, and a shorter time between GBM diagnosis and its recurrence. Patients who received chemotherapy in combination with other treatments (surgery and/or radiation therapy) at GBM recurrence had a longer survival than those in palliative care (
p
< 0.001). Surgery or radiation therapy alone did not have any effect on survival as compared with palliative care (
p
< 0.001).
Conclusion
This study confirms the importance of a multidisciplinary approach even at GBM recurrence, suggesting that combination treatments play a key role in management of disease.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35641731</pmid><doi>10.1007/s10072-022-06172-y</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5747-2808</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-1874 |
| ispartof | Neurological sciences, 2022-09, Vol.43 (9), p.5533-5541 |
| issn | 1590-1874 1590-3478 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2672319911 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Brain cancer Chemotherapy Clinical trials Diagnosis Glioblastoma Medicine Medicine & Public Health Neurology Neuroradiology Neurosciences Neurosurgery Oncology Original Article Palliative care Patients Psychiatry Radiation therapy Surgery Survival |
| title | Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit “Regina Elena” National Cancer Institute |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A06%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrent%20glioblastoma:%20which%20treatment?%20A%20real-world%20study%20from%20the%20Neuro-oncology%20Unit%20%E2%80%9CRegina%20Elena%E2%80%9D%20National%20Cancer%20Institute&rft.jtitle=Neurological%20sciences&rft.au=Villani,%20Veronica&rft.date=2022-09-01&rft.volume=43&rft.issue=9&rft.spage=5533&rft.epage=5541&rft.pages=5533-5541&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-022-06172-y&rft_dat=%3Cproquest_cross%3E2703182176%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2703182176&rft_id=info:pmid/35641731&rfr_iscdi=true |